Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 850 mci - drugs used in diabetes

Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Malta - English - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Malta - English - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

United States - English - NLM (National Library of Medicine)

cardinal health - rosiglitazone maleate (unii: kx2339dp44) (rosiglitazone - unii:05v02f2kdg) - rosiglitazone maleate 4 mg

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 1.25 mg - glyburide and metformin hydrochloride tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73m2) (see warnings and precautions). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. - concomitant administration of bosentan.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 5 mg - glyburide and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with: - renal disease or renal dysfunction (eg., as suggested by serum creatinine levels ≥ 1.5 mg/dl [males], ≥ 1.4 mg/dl [females], or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings and precautions). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. glyburide and metformin hydrochloride should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 2.5 mg - glyburide and metformin hydrochloride tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets is contraindicated in patients with : - renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dl [males], ≥1.4 mg/dl [females], or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings and precautions). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. - concomitant administration of bosentan. glyburide and metformin hydrochloride tablets should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - sitagliptin phosphate (unii: ts63ew8x6f) (sitagliptin - unii:qfp0p1dv7z), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - janumet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use janumet should not be used in patients with type 1 diabetes mellitus. janumet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using janumet. [see warnings and precautions (5.2).] janumet is contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m 2 ) [see warnings and precautions (5.1)] . - acute or chronic metabolic acidosis, including diabetic ketoacidosis. - history of a serious hypersensitivity reaction to janumet, sitagliptin, or metformin, such as anaphylaxis or angioedema. [see warnings and precautions (5.7); adverse reactions (6.2).] pregnanc

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as phosphate salt - tablets extended release - sitagliptin as phosphate salt 100 mg; metformin hydrochloride 1000 mg - metformin - januet xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate